Informatie:
Fout:
ID
13776
Beschrijving
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations; ODM derived from: https://clinicaltrials.gov/show/NCT01372384
Link
https://clinicaltrials.gov/show/NCT01372384
Trefwoorden
Versies (1)
- 06-03-16 06-03-16 -
Geüploaded op
6 maart 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Non-Squamous Non-Small Cell Lung Cancer NCT01372384
Eligibility Non-Squamous Non-Small Cell Lung Cancer NCT01372384
- StudyEvent: Eligibility
Similar models
Eligibility Non-Squamous Non-Small Cell Lung Cancer NCT01372384
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
age
Item
adult patients, >/= 18 years of age
boolean
C0001779 (UMLS CUI [1])
non-small cell lung cancer; Tyrosine kinase mutation; epidermal growth factor receptor
Item
locally advanced (stage iiib), metastatic (stage iv) or recurrent non-small cell lung cancer with mutations in the tyrosine kinase domain of the epidermal growth factor receptor (egfr)
boolean
C0007131 (UMLS CUI [1])
C3267004 (UMLS CUI [2])
C0034802 (UMLS CUI [3])
C3267004 (UMLS CUI [2])
C0034802 (UMLS CUI [3])
lesion
Item
at least one measurable lesion according to recist criteria
boolean
C0221198 (UMLS CUI [1])
ecog
Item
european cooperative oncology group (ecog) performance status 0-2
boolean
C1520224 (UMLS CUI [1])
liver function; renal function; Hematologic function
Item
adequate hematological, liver and renal function
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0221130 (UMLS CUI [3])
C0232804 (UMLS CUI [2])
C0221130 (UMLS CUI [3])
Cerebral metastasis; radiotherapy; surgery
Item
patients with stable cerebral metastases who have received surgical or radiotherapy will be eligible
boolean
C0555278 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C0543467 (UMLS CUI [3])
C1522449 (UMLS CUI [2])
C0543467 (UMLS CUI [3])
chemotherapy; therapy egfr; Neoadjuvant Therapy; adjuvant therapy; surgery
Item
previous chemotherapy or therapy against egfr for metastatic disease (neoadjuvant or adjuvant therapy after radical surgery is allowed if finalized >/= 6 months before entering the study)
boolean
C0392920 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C0034802 (UMLS CUI [2,2])
C0600558 (UMLS CUI [3])
C0677850 (UMLS CUI [4])
C0543467 (UMLS CUI [5])
C0087111 (UMLS CUI [2,1])
C0034802 (UMLS CUI [2,2])
C0600558 (UMLS CUI [3])
C0677850 (UMLS CUI [4])
C0543467 (UMLS CUI [5])
cervix carcinoma in situ; basal cell skin carcinoma; prostate carcinoma; good prognosis
Item
history of another neoplasm except for carcinoma in situ of the cervix, adequately treated basal cell skin carcinoma, radically treated prostate carcinoma with good prognosis (gleason </= 6), or another curatively treated neoplasm without evidence of disease in the last 5 years
boolean
C0851140 (UMLS CUI [1])
C0007117 (UMLS CUI [2])
C0600139 (UMLS CUI [3])
C0278250 (UMLS CUI [4])
C0007117 (UMLS CUI [2])
C0600139 (UMLS CUI [3])
C0278250 (UMLS CUI [4])
cerebral metastasis
Item
symptomatic cerebral metastases
boolean
C0555278 (UMLS CUI [1])
Eye Abnormalities
Item
any significant ophthalmologic abnormality
boolean
C0015393 (UMLS CUI [1])
Coumarins
Item
use of coumarins
boolean
C0010207 (UMLS CUI [1])
pregnancy; lactating
Item
pregnant or breast-feeding women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
pulmonary fibrosis; Lymphangiosis carcinomatosa
Item
pre-existing parenchymal lung disease such as pulmonary fibrosis, lymphangiosis and carcinomatosis (if this is the only presence of the disease)
boolean
C0034069 (UMLS CUI [1])
C0948588 (UMLS CUI [2])
C0948588 (UMLS CUI [2])